Clearmind Medicine Inc. Form 6-K Summary
Business Context and Reporting Period
This Form 6-K report covers the month of April 2026 for Clearmind Medicine Inc., a foreign private issuer headquartered in Vancouver, British Columbia. The filing details specific corporate actions regarding convertible debt instruments entered into with investors (CLA Investors) under a prior securities purchase agreement dated September 17, 2025.
Key Financial Metrics and Transactions
The filing does not provide comprehensive financial statements, revenue, profit, or cash flow data. It focuses on the following specific transaction metrics:
- Convertible Promissory Notes Issued: On April 14, 2026, the Company issued notes with an aggregate principal amount of $1,750,000.
- Cash Proceeds: The aggregate purchase price paid in cash was $1,575,000 (90% of the principal amount).
- Debt Conversion: On April 15, 2026, investors converted $875,000 of the principal amount into common shares.
- Conversion Price: The agreed conversion price was $0.60 per common share.
- Price Floor Amendment: The floor price for the remaining Promissory Notes was amended to $0.60 per common share.
Material Changes
The primary material change reported is the partial conversion of debt to equity and the amendment of the price floor mechanism. Specifically, $875,000 of the $1,750,000 principal issued on April 14 was immediately converted, reducing the outstanding debt principal by 50% of the recent issuance. The filing does not provide comparative financial data against prior periods.
Guidance, Outlook, and Risks
The filing contains no forward-looking guidance, management commentary on future operations, or specific risk factors beyond the standard incorporation by reference to prior registration statements. The transaction is described as a fulfillment of the terms of the September 2025 Securities Purchase Agreements (SPAs). No unusual items or contingencies are disclosed in this specific report.
Investor Verification Checklist
- Verify the exact number of common shares issued upon the conversion of the $875,000 principal at the $0.60 price.
- Confirm the remaining outstanding principal balance of the Promissory Notes following the conversion.
- Review the full text of the Conversion Agreement (Exhibit 10.1) for any additional covenants or conditions attached to the amended floor price.
- Check subsequent filings for the impact of this equity issuance on total share count and potential dilution.